BioSpace News Archive

Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced the close of a $21.5 million Series B financing.

Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, announced that it received notice from The Nasdaq Stock Market LLC on October 3, 2022 informing Sonnet that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

Endpoint Health, Inc., a Precision-FirstTM therapeutics company, unveiled its newest precision immunology program targeting inflammation mediated by tissue factor -dependent intracellular signaling.

AviadoBio announced the promotions of Graeme Fielder, Ph.D. to Chief Operating Officer and Alex Bloom, Ph.D. to Chief Technical Officer.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 33 newly-hired employees stock options to purchase an aggregate of 522,808 shares, and restricted stock units covering an aggregate of 166,916 shares, of BioCryst common stock.

Freeline Therapeutics Holdings plc announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads to progressive organ damage and can result in early death as a result of a harmful build-up of fat in cells due to an enzyme deficiency.

CytoSorbents Corporation announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12th, 2022. Company management will also meet with investors in 1x1 meetings throughout the conference.

Aeglea BioTherapeutics, Inc. today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystin is underway.

Fewer participants treated with SNG001 compared to placebo progressed to hospitalisation (1/110 vs 7/110, P=0.07).

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to announce the recipients of our 2022 VA Research Scholar Awards.